Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Apitegromab

MARKETED

anti-(pro/latent)-myostatin monoclonal antibody; muscle-preserving combo with GIP/GLP-1 dual agonist

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 0Very low evidence 1

Apitegromab is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Apitegromab MARKETED
Body composition Mixed
Very low evidence

Scholar Rock phase-2 EMBRAZE trial (NCT06445075): apitegromab added to tirzepatide preserved additional lean mass versus tirzepatide alone over 24 weeks. The only...

Scholar Rock, EMBRAZE phase-2 topline press release, 18 Jun 2025; NCT06445075 Source
Full findingScholar Rock phase-2 EMBRAZE trial (NCT06445075): apitegromab added to tirzepatide preserved additional lean mass versus tirzepatide alone over 24 weeks. The only major muscle-preservation combo studied on TIRZEPATIDE (a GIP/GLP-1 dual agonist) rather than semaglutide. NON-GRADUATING: company press topline only.
PopulationEMBRAZE phase-2 RCT, N=102, double-blind placebo-controlled, 24 weeks, adults overweight/obese; apitegromab 10 mg/kg IV q4w + tirzepatide vs placebo + tirzepatide.
Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)
Scope limitssmall sample (N~102)
Comparatorsplacebo + tirzepatide